Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-006728
Filing Date
2025-04-30
Accepted
2025-04-29 20:56:12
Documents
17
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 284371
2 ex10-18.htm EX-10.18 16655
3 ex31-1.htm EX-31.1 7044
4 ex31-2.htm EX-31.2 6711
  Complete submission text file 0001641172-25-006728.txt   832990

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ltrn-20241231.xsd EX-101.SCH 17515
6 XBRL DEFINITION FILE ltrn-20241231_def.xml EX-101.DEF 6249
7 XBRL LABEL FILE ltrn-20241231_lab.xml EX-101.LAB 137598
8 XBRL PRESENTATION FILE ltrn-20241231_pre.xml EX-101.PRE 72737
19 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 8908
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39318 | Film No.: 25890472
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)